Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain

Pillay, Selvan; Pillay, Viness; Choonara, Yahya E.; Naidoo, Dinesh; Khan, Riaz A.; Toit, Lisa C. du; Ndesendo, Valence M. K.; Modi, Girish; Danckwerts, Michael P.; Iyuke, Sunny E.

doi:10.1016/j.ijpharm.2009.08.021

Cited by 73 publications

(35 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to restore striatal DA content, Pillay et al developed an intracranial nano-enabled scaffold device (NESD) for DA site-specific delivery [35]. The NESD was modulated through biometric simulation and computational prototyping to produce a binary crosslinked alginate scaffold embedding stable DA-loaded cellulose acetate phthalate NP.…”

Section: Dds For Dopamine Deliverymentioning

confidence: 99%

Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems

2013

View full text Add to dashboard Cite

Current treatments for Parkinson's disease (PD) are aimed at addressing motor symptoms but there is no therapy focused on modifying the course of the disease.Successful treatment strategies have been so far limited and brain drug delivery remains a major challenge that restricts its treatment. This review provides an overview of the most promising emerging agents in the field of PD drug discovery, discussing improvements that have been made in brain drug delivery for PD. It will be shown that new approaches able to extend the length of the treatment, to release the drug in a continuous manner or to cross the blood brain barrier and target a specific region are still needed.Overall, the results reviewed here show that there is an urgent need to develop both symptomatic and disease-modifying treatments, giving priority to neuroprotective treatments. Promising perspectives are being provided in this field by rasagiline and by neurotrophic factors like glial cell line-derived neurotrophic factor. The identification of disease-relevant genes has also encouraged the search for disease-modifying therapies that function by identifying molecularly-targeted drugs. The advent of new molecular and cellular targets like α-synuclein, leucine-rich repeat serine/threonine protein kinase 2 or parkin, among others, will require innovative delivery therapies. In this regard, drug delivery systems (DDS) have shown great potential for improving the efficacy of conventional and new PD therapy and reducing its side effects. The new DDS discussed here, which include microparticles, nanoparticles and hydrogels among others, will probably open up possibilities that extend beyond symptomatic relief. However, further work needs to be done before DDS become a therapeutic option for PD patients.

show abstract

Section: Dds For Dopamine Deliverymentioning

confidence: 99%

Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems

2013

View full text Add to dashboard Cite

show abstract

“…The site-specific delivery of DA from an intracranial nano-enable scaffold device (NESD) implanted in the frontal lobe parenchyma was proposed for Pillay et al [302]. The NESD is composed of a binary crosslinked alginate scaffold containing cellulose acetate phthalate NP loaded with DA.…”

Section: Invasive Methods; Local Administrationmentioning

confidence: 99%

Diagnostic and Therapeutic Uses of Nanomaterials in the Brain

Garbayo¹,

Mendoza²,

Blanco-Prieto

2014

CMC

View full text Add to dashboard Cite

Nanomedicine has recently emerged as an exciting tool able to improve the early diagnosis and treatment of a variety of intractable or age-related brain disorders. The most relevant properties of nanomaterials are that they can be engineered in such a way that they can cross the blood brain barrier, with the final aim of targeting specific cells and molecules and to act as vehicles for drugs. Potentially beneficial properties of nanotherapeutics derived from its unique characteristics include improved efficacy, safety, sensitivity and personalization compared to conventional medicines.In this review, recent advances in available nanostructures and nanomaterials for brain applications will be described. Then, the latest nanotechnological applications for the treatment and diagnosis of neurological disorders, mainly brain tumors and neurodegenerative diseases, will be reviewed. Recent investigations of the neurotoxicity of the nanomaterial both in vitro and in vivo will be summarized. Finally, the ongoing challenges that have to be meet if new nanomedical products are to be put on the market will be discussed and some future directions will be outlined.

show abstract

“…Thus, new L-dopa formulation using NPs has been proposed: chitosan-coated NPs [197] and tested in vitro for toxicity [198]. An intrathecal implanted system allowing a site-specific controlled release of cellulose acetate phthalate NPs loaded with dopamine during a period of time was designed and evaluated in a rat model for the establishment of PD chronic drug delivery system [199]. Similarly, encapsulation of bromocriptin in NPs was also tested [200], but the finality of such approaches has especially an interest in the elaboration of effectiveness and non-invasive drug delivery systems targeting brain pathologies.…”

Section: Therapeutic Strategies Using Nanoparticles In Ndmentioning

confidence: 99%

The Ins and Outs of Nanoparticle Technology in Neurodegenerative Diseases and Cancer

Wilson¹,

Magnaudeix²,

Naves³

et al. 2015

CDM

View full text Add to dashboard Cite

Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain

Cited by 73 publications

References 28 publications

Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems

Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems

Diagnostic and Therapeutic Uses of Nanomaterials in the Brain

The Ins and Outs of Nanoparticle Technology in Neurodegenerative Diseases and Cancer

Contact Info

Product

Resources

About